The approval of Zynquesta is inevitable at this point. The data supports it efficacy and it's safety profile. The FDA's concern about DKA will be a moot point with the release of the continuous glucose and ketone monitor from Abbott. Some of the estimates I've seen put sales above a billion dollars a year.